Kacinox Injection contains Amikacin sulfate equivalent to 500 mg per 2 ml and is an aminoglycoside antibiotic indicated for the treatment of serious bacterial infections caused by susceptible strains of aerobic Gram-negative bacteria. It is primarily used in severe infections such as septicemia, respiratory tract infections, urinary tract infections, intra-abdominal infections, bone and joint infections, and complicated skin and soft tissue infections. Amikacin exerts its bactericidal effect by binding irreversibly to the 30S ribosomal subunit, inhibiting protein synthesis and leading to bacterial cell death. Kacinox Injection is administered via intramuscular or intravenous routes under strict medical supervision, with dosage adjustments required based on renal function and severity of infection. Monitoring of serum drug levels is recommended to minimize the risk of nephrotoxicity and ototoxicity, which are the primary adverse effects associated with aminoglycosides. Caution is advised in patients with pre-existing renal impairment, neuromuscular disorders, or those receiving concurrent ototoxic or nephrotoxic agents. Kacinox should be used only when clearly indicated, following susceptibility testing to ensure efficacy. Proper hydration and renal function monitoring are essential during therapy to optimize safety and therapeutic outcomes.